Market capitalization | $1.09b |
Enterprise Value | $667.19m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 63.54 |
P/S ratio (TTM) P/S ratio | 103.38 |
P/B ratio (TTM) P/B ratio | 2.06 |
Revenue growth (TTM) Revenue growth | 40.22% |
Revenue (TTM) Revenue | $10.50m |
As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.
9 Analysts have issued a Autolus Therapeutics plc forecast:
9 Analysts have issued a Autolus Therapeutics plc forecast:
Dec '23 |
+/-
%
|
||
Revenue | 1.70 1.70 |
73%
73%
|
|
Gross Profit | -4.87 -4.87 |
-
|
|
EBITDA | -188 -188 |
18%
18%
|
EBIT (Operating Income) EBIT | -195 -195 |
16%
16%
|
Net Profit | -208 -208 |
40%
40%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
Head office | United Kingdom |
CEO | Christian Itin |
Employees | 463 |
Founded | 2014 |
Website | www.autolus.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.